Canopy Health Innovations (CHI) is a cannabis incubator focused on developing and researching clinically ready, whole plant cannabis drug formulations and dose delivery systems. The ultimate goal is to validate diversified treatment options for Canadians and for patients and consumers in other jurisdictions where treatment with cannabis is federally lawful. The foundation of our research and development plan is to improve the quality of life and health of those suffering from acute and chronic illnesses. The proper formulation of cannabinoids have the opportunity to improve a number of common complaints and ailments such as pain, appetite stimulation, and sleep quality. Medical cannabis is also used to manage increasingly common diseases such as Dementia, Alzheimer’s, Autism, Crohn’s Disease and Colitis, and Fibromyalgia. Canopy Animal Health is a wholly-owned subsidiary of Canopy Health, focused on creating cannabis-based healthcare products for companion animals. Our goal is to provide family pets with specialized cannabinoid medicines to maintain, improve or extend their quality of life. Canopy Health has undertaken an extensive intellectual property review which forms the basis of all of our strategic plans.